Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2020 Apr 9;146(4):901–911. doi: 10.1016/j.jaci.2019.11.051

FIG 5.

FIG 5.

Main clinical findings in patients with damaging NFKB1 mutations. Percentage distribution of clinical manifestations (A), and infection types (B). CMV, Cytomegalovirus; GLILD, granulomatous-lymphocytic interstitial lung disease; HAV, hepatitis A virus; IBD, inflammatory bowel disease; JC virus, John Cunningham virus.